Некатегоризовані сторінки

Перейти до: навігація, пошук

Нижче показано до 50 результати у діапазоні від #9541 до #9590.

Переглянути (попередні 50наступні 50) (2050100250500).

  1. Aking the decision about her daughter's vaccination, even when she
  2. Akt in our chondrosarcoma design 1 are not able to put apart the likelihood that resistance could emerge
  3. Akt in our chondrosarcoma product one particular cannot place apart the probability that resistance could arise
  4. Akt inhibitor-Toddler Has Tested The Most Up-To-Date Formula - Make A Fortune Completely From Scratch
  5. Akt inhibitor Tasks You Will Be Able To Do Yourself
  6. Akt inhibitor Will Teach You New Maneuvers - Today We Stroll Into The Procedure
  7. Al., 2006; de Lange et al., 2008; Muller et al., 2011). Some studies offered
  8. Al. 2015; Fu et al. 2015). It has been documented that the incidence
  9. Al. BMJ Open 2016;6:e014022. doi:10.1136/bmjopen-2016-Open AccessFigure 1 Paramedic Pathfinder tool
  10. Al. BMJ Open 2016;6:e014022. doi:ten.1136/bmjopen-2016-Open AccessFigure 1 Paramedic Pathfinder tool
  11. Al. BMJ Open 2016;six:e014022. doi:10.1136/bmjopen-2016-Open AccessFigure 1 Paramedic Pathfinder tool
  12. Al. BMJ Open 2016;six:e014022. doi:ten.1136/bmjopen-2016-Open AccessFigure 1 Paramedic Pathfinder tool
  13. Al Ajwa Dates
  14. Al Bojko Reviews
  15. Al aromatherapy, readers are referred to and. Amongst the Japanese persons
  16. Al challenges. About four.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  17. Al challenges. Around 4.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  18. Al challenges. Around 4.9 of the* Correspondence: soloteferra@yahoo.com 1 Division of
  19. Al complications. About 4.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  20. Al complications. About four.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  21. Al complications. Around 4.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  22. Al difficulties. About four.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  23. Al difficulties. Around four.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  24. Al issues. Around 4.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  25. Al issues. Around four.9 of the* Correspondence: soloteferra@yahoo.com 1 Division of
  26. Al models that are sensitive for the lytic function of all
  27. Al models that are sensitive to the lytic function of all
  28. Al models that are sensitive towards the lytic function of all
  29. Al models that happen to be sensitive for the lytic function of all
  30. Al models that happen to be sensitive to the lytic function of all
  31. Al models that happen to be sensitive towards the lytic function of all
  32. Al models which are sensitive to the lytic function of all
  33. Al models which can be sensitive for the lytic function of all
  34. Al models which can be sensitive to the lytic function of all
  35. Al models which can be sensitive towards the lytic function of all
  36. Al models which might be sensitive for the lytic function of all
  37. Al models which might be sensitive to the lytic function of all
  38. Al models which might be sensitive towards the lytic function of all
  39. Al or specific subgroups. Future research have to have to very carefully contemplate these
  40. Al oxygen extraction (13). BOLD contrast adds to a related, emerging set
  41. Al problems. About four.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  42. Al problems. About four.9 of the* Correspondence: soloteferra@yahoo.com 1 Division of
  43. Al recommendations, corrected the whole manuscript, and ready the final version.
  44. Al to lessen interest in STEM fields amongst women and individuals
  45. Al troubles. About four.9 of the* Correspondence: soloteferra@yahoo.com 1 Department of
  46. Al variation.20 For research assessing exposure based around the residence at
  47. Al variation.20 For research assessing exposure based on the residence at
  48. Al variation.20 For research assessing exposure primarily based around the residence at
  49. Al variation.20 For research assessing exposure primarily based on the residence at
  50. Al variation.20 For studies assessing exposure based around the residence at

Переглянути (попередні 50наступні 50) (2050100250500).